Search News & Insights
Matheson advises Royalty Pharma on revised $6.5 billion hostile bid for Elan
Matheson continues to advise Royalty Pharma on its $6.5 billion cash offer for Elan Corporation plc, the Irish biotechnology company. On 20 May 2013, Royalty Pharma revised its hostile offer for the NASDAQ-listed Elan Corporation.
This is the latest in a number of high-profile multi-billion dollar transactions that Matheson has advised on.
Matheson is also advising the US pharmaceutical firm Actavis on its $5.1 billion acquisition of Dublin-based Warner Chilcott. The all-stock deal was announced on 20 May 2013 and the acquisition is expected to be completed by the end of the year.
In February of this year, Matheson advised on the sale of the country's biggest life and pensions provider Irish Life to Canada Life parent, Great-West Lifeco. The firm advised Ireland's Minister for Finance on the €1.3 billion sale, which has been described as a "historic transaction."
Matheson recently advised Eaton Corporation plc on its $11.8 billion acquisition of Cooper Industries. This was the largest single M&A transaction in Ireland during 2012 and was named 'Most Innovative Deal of the Year' at the Finance Dublin 2013 Awards.
Matheson is the law firm of choice for international companies and financial institutions doing business in and through Ireland.